Novartis Pharma AG: Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
The study plans to enroll 2100 patients, with 400 patients to be enrolled into
Phase 2, followed by 1700 patients in Phase 3
Novartis has been granted an option from Molecular Partners to in-license global rights of ensovibep and MP0423 - DARPin antiviral therapeutic candidates that are undergoing testing to target SARS-CoV-2 spike protein
DARPin therapeutics well suited for a pandemic setting due to multi-specific target binding, long half-life for sustained activity and highly scalable production, compared to monoclonal antibodies
Basel, May 27, 2021 - Novartis and Molecular Partners announced today the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin
It’s been almost 10 years since the world was warned of a post-antibiotic apocalypse. Katrina Megget takes a look at the initiatives trying to support antimicrobial R&D
Search jobs Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
- The Ministry of Health, Labour and Welfare (MHLW) Grants Regulatory Approval of Moderna’s COVID-19 Vaccine (COVID-19 Vaccine Moderna Intramuscular Injection) Following Positive Interim Results in Takeda’s Phase 1/2 Immunogenicity and Safety Clinical Trial
- Interim Results Indicate Immune Response Consistent with Moderna’s Pivotal Phase 3 COVE Trial Results
- Takeda Will Immediately Begin Distribution in Japan
OSAKA, Japan, May 21, 2021 Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna’s mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan. The approval is based on positive clinical data from Takeda’s
Grifols takes another step in the fight against Alzheimer s, partners with Ace to open first AMBAR Center in Barcelona
-
AMBAR Center combines Grifols more than 15 years of knowledge researching this devastating disease with the experience of the non-profit medical foundation Ace Alzheimer Center Barcelona in diagnosing and treating Alzheimer s patients, including application of AMBAR (Alzheimer Management by Albumin Replacement)
-
The AMBAR clinical program, based on periodic plasma exchange with albumin, has shown a delay in the cognitive and functional progression of Alzheimer s disease in mild-to-moderate patients
- Ace Alzheimer Center will manage the center, to be located on its premises in Barcelona. Grifols will partner with other leading medical institutions to open expected future centers in the EU, U.S. and China, obtaining AMBAR
Grifols takes another step in the fight against Alzheimer s, partners with Ace to open first AMBAR® Center in Barcelona
News provided by
Share this article
-
AMBAR
® Center combines Grifols more than 15 years of knowledge researching this devastating disease with the experience of the non-profit medical foundation Ace Alzheimer Center Barcelona in diagnosing and treating Alzheimer s patients, including application of AMBAR
® (Alzheimer Management by Albumin Replacement)
-
The AMBAR
® clinical program, based on periodic plasma exchange with albumin, has shown a delay in the cognitive and functional progression of Alzheimer s disease in mild-to-moderate patients
- Ace Alzheimer Center will manage the center, to be located on its premises in Barcelona. Grifols will partner with other leading medical institutions to open expected future centers in the EU, U.S. and China, obtaining AMBAR